Chemomab Therapeutics (NASDAQ: CMMB), is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases.
Chemomab is making great strides with its novel CM-101 proprietary platform, which hinders the fundamental function of the soluble chemokine CCL24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders.
CM-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets CCL24. Chemomab has shown that CM-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action.
Chemomab is actively advancing CM-101 into phase 2 studies to treat patients with liver fibrosis (Primary Sclerosing Cholangitis) and patients suffering from skin and lung fibrosis (Systemic Sclerosis).
Location: Israel, Tel Aviv District, Tel Aviv
Employees: 11-50
Total raised: $10M
Founded date: 2011
Investors 3
| Date | Name | Website |
| - | Altium Cap... | altiumcap.... |
| - | Shavit Cap... | shavitcapi... |
| - | OrbiMed | orbimed.co... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 04.12.2017 | Series B | $10M | - | finsmes.co... |
Mentions in press and media 27
| Date | Title | Description | Source |
| 12.01.2023 | Revive Therapeutics Ltd. Closes $4.3 Million Offering | - | globenewsw... |
| 30.11.2022 | Revive Therapeutics Ltd. Announces Offering of Up to $5 Mill... | - | globenewsw... |
| 17.12.2021 | Chemomab Therapeutics Announces Expected Appointment of Dale... | TEL AVIV, Israel, Dec. 16, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab... | marketscre... |
| 03.12.2021 | Chemomab Therapeutics Names David M. Weiner, MD as Interim C... | TEL AVIV, Israel, Dec. 3, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ: CMMB), (Chemomab)... | marketscre... |
| 02.12.2021 | Chemomab Announces FDA Clearance of Its IND Application for ... | TEL AVIV, Israel, Dec. 2, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab)... | marketscre... |
| 12.11.2021 | Chemomab Therapeutics Announces Third Quarter 2021 Financial... | TEL AVIV, Israel, Nov. 12, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab... | marketscre... |
| 08.11.2021 | Chemomab Therapeutics Names Donald R. Marvin Chief Financial... | TEL AVIV, Israel, Nov. 8, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab)... | marketscre... |
| 27.09.2021 | Chemomab Therapeutics : Announces Collaboration with Leeds U... | TEL AVIV, Israel, Sept. 27, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ("Ch... | marketscre... |
| 02.09.2021 | Chemomab Therapeutics Announces Appointment of Dale Pfost as... | TEL AVIV, Israel, Sept. 2, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clini... | prnewswire... |
| 02.09.2021 | Chemomab Therapeutics : Announces Appointment of Dale Pfost ... | TEL AVIV, Israel, Sept. 2, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinica... | marketscre... |
Show more